Ignite Creation Date:
2024-05-06 @ 12:16 AM
Last Modification Date:
2024-10-26 @ 10:47 AM
Study NCT ID:
NCT01534260
Status:
COMPLETED
Last Update Posted:
2018-08-17
First Post:
2012-02-13
Brief Title:
Phase III Study of Combination of Sorafenib Vorinostat and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk Monosomy 57 Cytogenetics or FLT3-ITD Positive Genotype
Sponsor:
Hamid Sayar
Organization:
Indiana University
Organization Data
Organization:
Indiana University
Class:
OTHER
Study ID:
IUCRO-0327
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Hamid Sayar
Lead Sponsor Class:
OTHER
Responsible Party:
Hamid Sayar
Responsible Party Title:
Assistant Professor of Clinical Medicine
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Indiana University
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Millennium Pharmaceuticals Inc | INDUSTRY |
| Bayer | INDUSTRY |
| Merck Sharp Dohme LLC | INDUSTRY |